Tautomycetin induces apoptosis by inactivating Akt through a PP1-independent signaling pathway in human breast cancer cells

Journal of Pharmacological Sciences

Volumn 121, Issue 1, 2013, Pages 17-24

  Niu, Mingshan ^a   Sun, Yan ^a   Liu, Xuejiao ^a   Tang, Li ^a   Qiu, Rongguo ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Akt pathway; Apoptosis; Breast cancer; Tautomycetin

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BETA CATENIN; CASPASE 7; CASPASE 8; CASPASE 9; CYTOCHROME C; FORKHEAD TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; PROTEIN PHOSPHATASE PP1; TAUTOMYCETIN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

EID: 84873855479     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12206FP     Document Type: Article

References (30)

1. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res. 2008;68: 1905-1915.
2. Kim JH, Kim MS, Bak Y, Chung IM, Yoon DY. The cadin-2en-1β-ol- 1β-D-glucuronepyranoside suppresses TPA-midiated matrix metalloproteinase-9 expression through the ERK signaling pathway in MCF-7 human breast adenocarcinoma cells. J Pharmacol Sci. 2012;118:198-205.
3. Faneyte IF, Kristel PMP, Maliepaard M, Scheffer GL, Scheper RJ, Schellens JH, et al. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res. 2002;8:1068-1074.
4. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003; 66:1022-1037.
5. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Bio. 2006;7:505-516.
6. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene. 1998;17:313-325.
7. Yoo KD, Park ES, Lim Y, Kang S, Yoo SH, Won H, et al. Clitocybin A, a novel isoindolinone, from mushroom Clitocybe aurantiaca, inhibits cell proliferation through G1 phase arrest by regulating the PI3K/Akt cascade in vascular smooth muscle cells. J Pharmacol Sci. 2012;118:171-177.
8. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-242.
9. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-868.
10. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318-1321.
11. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000;19:2324-2330.
12. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003;22:3205-3212.
13. Carson JP, Kulik G, Weber MJ. Antiapoptotic signaling in LNCaP prostate cancer cells. Cancer Res. 1999;59:1449-1453.
14. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, Sethi T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res. 1998;58:5239-5247.
15. Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer. 2002;94:3127-3134.
16. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986-3997.
17. Cheng XC, Kihara T, Ying X, Uramoto M, Osada H, Kusakabe H, et al. A new antibiotic, tautomycetin. J Antibiot. 1989;42: 141-144.
18. Mitsuhashi S, Matsuura N, Ubukata M, Oikawa H, Shima H, Kikuchi K. Tautomycetin is a novel and specific inhibitor of serine/threonine protein phosphatase type 1, PP1. Biochem Bioph Res Co. 2001;287:328-331.
19. Ishihara H, Martin B, Brautigan D, Karaki H, Ozaki H, Kato Y, et al. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Bioph Res Co. 1989;159:871-877.
20. Li YM, Casida JE. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sci U S A. 1992;89: 11867-11870.
21. Roberge M, Tudan C, Hung SMF, Harder KW, Jirik FR, Anderson H. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res. 1994;54: 6115-6121.
22. Heneberg P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr Med Chem. 2009; 16:706-733.
23. Shim JH, Lee HK, Chang EJ, Chae WJ, Han JH, Han DJ, et al. Immunosuppressive effects of tautomycetin in vivo and in vitro via T cell-specific apoptosis induction. Proc Natl Acad Sci U S A. 2002;99:10617-10622.
24. Lee JH, Lee JS, Kim SE, Moon BS, Kim YC, Lee SK, et al. Tautomycetin inhibits growth of colorectal cancer cells through p21cip/WAF1 induction via the extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2006;5:3222-3231.
25. Adler JT, Cook M, Luo Y, Pitt SC, Ju J, Li W, et al. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3β. Mol Cancer Ther. 2009;8:914-920.
26. Niu M, Sun Y, Liu B, Tang L, Qiu R. Differential effects of tautomycetin and its derivatives on protein phosphatase inhibition, immunosuppressive function and antitumor activity. Korean J Physiol Pha. 2012;16:145-151.
27. Van Dessel N, Beke L, Görnemann J, Minnebo N, Beullens M, Tanuma N, et al. The phosphatase interactor NIPP1 regulates the occupancy of the histone methyltransferase EZH2 at Polycomb targets. Nucleic Acids Res. 2010;38:7500-7512.
28. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Gene Dev. 1999;13:1899-1911.
29. Liang Y, Yan C, Schor NF. Apoptosis in the absence of caspase 3. Oncogene. 2001;20:6570.
30. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988-1004.